利肺健脾方联合化疗治疗晚期非小细胞肺癌临床疗效观察  被引量:13

Clinical effect observation of Lifei Jianpi Decoction combined with chemotherapy in treating patients with advanced non-small cell lung cancer

在线阅读下载全文

作  者:朱渊红[1] 吕昕[1] 徐婷贞[1] 

机构地区:[1]浙江中医药大学附属第一医院,杭州310006

出  处:《中华中医药杂志》2017年第1期360-362,共3页China Journal of Traditional Chinese Medicine and Pharmacy

基  金:浙江省中医药科学研究基金计划项目(No.2011ZA028)~~

摘  要:目的:观察利肺健脾方联合化疗治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法:63例晚期NSCLC患者随机分为两组,治疗组(32例)给予利肺健脾方联合GP或DP方案化疗,对照组(31例)给予GP或DP方案化疗。治疗2个周期进行疗效评价。结果:在瘤灶近期疗效方面,治疗组的有效率和疾病控制率分别为43.8%和65.6%,对照组分别为38.7%和61.3%,两组差异无统计学意义。治疗后治疗组在KPS评分、细胞免疫功能及化疗不良反应方面优于对照组(P<0.05)。结论:利肺健脾方联合化疗治疗晚期NSCLC,可以改善患者的生活质量,提高患者的细胞免疫功能,减轻化疗的不良反应。Objective:To observe the clinical curative effect of Lifei Jianpi(LFJP) Decoction in association with chemotherapy in treating patients with advanced non-small cell lung cancer(NSCLC).Methods:Sixty-three patients with advanced NSCLC were randomly assigned to two groups.The 31 patients in the control group were only treated with chemotherapy of GP or DP regimen,and 32 patients in the treatment group were treated with the same chemotherapy and LFJP Decoction.The clinical efficacy was evaluated after two cycles of treatment.Results:In treatment group,the response rate(RR) was 43.8%,and disease control rate(DCR) was 65.6%.In control group,the RR was 38.7%,and DCR was 61.3%.The difference between two groups was not statistically significant.After treatment,the KPS score,cellular immune function and chemotherapy toxicity in the treatment group were statistically significant compared with that of control group(P〈0.05).Conclusion:LFJP combined with chemotherapy in treating advanced NSCLC can improve their quality of life,enhance their cell-mediated immune function and relive side effects and toxic effects caused by chemotherapy.

关 键 词:利肺健脾方 非小细胞肺癌 生活质量 调节性T细胞 细胞免疫 

分 类 号:R734.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象